Newamsterdam Pharma Stock Today
| NAMS Stock | 19.85 0.95 4.57% |
Performance9 of 100
| Odds Of DistressLess than 48
|
NewAmsterdam Pharma is selling for under 19.85 as of the 30th of November 2024; that is 4.57 percent down since the beginning of the trading day. The stock's lowest day price was 19.25. NewAmsterdam Pharma has 48 percent odds of going through some form of financial distress in the next two years and did not have a very good performance for investor during the last 90 trading days. Equity ratings for NewAmsterdam Pharma are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 3rd of June 2024 and ending today, the 30th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 23rd of November 2022 | Category Healthcare | Classification Health Care |
NewAmsterdam Pharma is entity of United States. It is traded as Stock on NASDAQ exchange. The company has 92.39 M outstanding shares of which 1.01 M shares are now shorted by private and institutional investors with about 2.92 trading days to cover. More on NewAmsterdam Pharma
Moving together with NewAmsterdam Stock
| 0.73 | VTRS | Viatris | PairCorr |
| 0.75 | ESPR | Esperion Therapeutics Buyout Trend | PairCorr |
| 0.66 | EWTX | Edgewise Therapeutics | PairCorr |
| 0.82 | BMY | Bristol Myers Squibb Sell-off Trend | PairCorr |
Moving against NewAmsterdam Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
NewAmsterdam Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President CEO | FACC Facp | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
NewAmsterdam Pharma can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand NewAmsterdam Pharma's financial leverage. It provides some insight into what part of NewAmsterdam Pharma's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
NewAmsterdam Pharma (NAMS) is traded on NASDAQ Exchange in USA. It is located in Gooimeer 2-35, Naarden, Netherlands, 1411 DC and employs 62 people. NewAmsterdam Pharma is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.29 B. NewAmsterdam Pharma conducts business under Biotechnology sector and is part of Health Care industry. The entity has 92.39 M outstanding shares of which 1.01 M shares are now shorted by private and institutional investors with about 2.92 trading days to cover.
NewAmsterdam Pharma generates negative cash flow from operations
Check NewAmsterdam Pharma Probability Of Bankruptcy
Ownership AllocationNewAmsterdam Pharma maintains a total of 92.39 Million outstanding shares. The majority of NewAmsterdam Pharma outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in NewAmsterdam Pharma to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in NewAmsterdam Pharma. Please pay attention to any change in the institutional holdings of NewAmsterdam Pharma as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check NewAmsterdam Ownership Details
NewAmsterdam Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Polar Capital Holdings Plc | 2024-06-30 | 1 M | |
| Deerfield Management Co | 2024-09-30 | 901.8 K | |
| Gmt Capital Corp | 2024-06-30 | 891.8 K | |
| Avidity Partners Management Lp | 2024-09-30 | 889.7 K | |
| Artal Group S A | 2024-06-30 | 800 K | |
| Pictet Asset Manangement Sa | 2024-06-30 | 683.7 K | |
| Citadel Advisors Llc | 2024-09-30 | 522.5 K | |
| Woodline Partners Lp | 2024-06-30 | 483.4 K | |
| Affinity Asset Advisors, Llc | 2024-09-30 | 472.4 K | |
| Fcpm Iii Services Bv | 2024-09-30 | 11.8 M | |
| Bain Capital Life Sciences Investors, Llc | 2024-09-30 | 10.5 M |
NewAmsterdam Pharma Historical Income Statement
NewAmsterdam Stock Against Markets
NewAmsterdam Pharma Corporate Management
| Louise Kooij | Treasurer, CFO | Profile | |
| Jim Jacobson | Chief Secretary | Profile | |
| Annie Neild | VP Affairs | Profile | |
| FESC MD | Chief Founder | Profile | |
| Marc MD | Chief Officer | Profile | |
| MSc MBA | Chief Officer | Profile | |
| Lina Gugucheva | Chief Officer | Profile |
Additional Tools for NewAmsterdam Stock Analysis
When running NewAmsterdam Pharma's price analysis, check to measure NewAmsterdam Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NewAmsterdam Pharma is operating at the current time. Most of NewAmsterdam Pharma's value examination focuses on studying past and present price action to predict the probability of NewAmsterdam Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NewAmsterdam Pharma's price. Additionally, you may evaluate how the addition of NewAmsterdam Pharma to your portfolios can decrease your overall portfolio volatility.